{
  "id": "critical-illness-myopathy-neuropathy",
  "title": "Critical Illness Myopathy/Neuropathy",
  "version": "1.1",
  "icd10": [
    "** G72.81 (Critical illness myopathy)",
    "G62.81 (Critical illness polyneuropathy)",
    "M62.81 (ICU-acquired weakness)"
  ],
  "scope": "** Diagnosis, management, and rehabilitation of ICU-acquired weakness (ICUAW) including critical illness myopathy (CIM), critical illness polyneuropathy (CIP), and combined CIM/CIP (CINM). Covers risk factor identification and modification, electrodiagnostic differentiation (NCS/EMG including direct muscle stimulation), MRC sum score assessment, supportive management, early mobilization, ventilator liberation strategies, nutritional optimization, and long-term prognosis. Excludes pre-existing neuromuscular disorders (GBS, myasthenia gravis, ALS), spinal cord injury, and prolonged neuromuscular blockade effect without underlying neuromyopathy.",
  "notes": [],
  "sections": {
    "Laboratory Workup": {
      "Essential/Core Labs": [
        {
          "item": "CBC with differential (CPT 85025)",
          "rationale": "Baseline; infection screen; leukocytosis suggests ongoing sepsis as risk factor for ICUAW",
          "target": "Normal; leukocytosis or bandemia suggest active infection",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "CMP (BMP + LFTs) (CPT 80053)",
          "rationale": "Electrolytes (K, Mg, Ca, Phos affect muscle function); renal/hepatic function; glucose control assessment",
          "target": "Normal; hyperglycemia >180 mg/dL requires insulin adjustment; electrolyte correction",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Magnesium (CPT 83735)",
          "rationale": "Hypomagnesemia worsens weakness and impairs neuromuscular transmission",
          "target": ">2.0 mg/dL; replete if low",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Phosphorus (CPT 84100)",
          "rationale": "Hypophosphatemia causes profound muscle weakness including respiratory muscles; may mimic or worsen ICUAW",
          "target": ">2.5 mg/dL; replete aggressively if <1.5 mg/dL",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Calcium (ionized) (CPT 82330)",
          "rationale": "Hypocalcemia increases neuromuscular excitability; hypercalcemia causes weakness",
          "target": "Normal ionized Ca 4.5-5.3 mg/dL",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Creatine kinase (CK) (CPT 82550)",
          "rationale": "Elevated in CIM (often moderately 1000-5000 IU/L); very high levels suggest rhabdomyolysis; normal in CIP",
          "target": "Mildly to moderately elevated in CIM; normal in CIP; >10,000 suggests rhabdomyolysis",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Blood glucose (CPT 82947)",
          "rationale": "Hyperglycemia is a major modifiable risk factor for ICUAW; target 140-180 mg/dL per NICE-SUGAR",
          "target": "140-180 mg/dL; avoid hypoglycemia <70 mg/dL",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Arterial blood gas (ABG) (CPT 82803)",
          "rationale": "Assess ventilation (PaCO2) and oxygenation; hypercapnia indicates respiratory muscle weakness contributing to ventilator dependence",
          "target": "Normal: pH 7.35-7.45, PaCO2 35-45; rising PaCO2 suggests respiratory muscle failure",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Lactate (CPT 83605)",
          "rationale": "Elevated in sepsis and tissue hypoperfusion; ongoing sepsis perpetuates ICUAW",
          "target": "<2.0 mmol/L",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Procalcitonin (CPT 84145)",
          "rationale": "Distinguish ongoing infection from inflammatory state; persistent sepsis worsens ICUAW prognosis",
          "target": "<0.5 ng/mL; elevated suggests active infection requiring treatment",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "TSH (CPT 84443)",
          "rationale": "Hypothyroid myopathy can mimic CIM; critical illness may cause sick euthyroid syndrome",
          "target": "Normal (interpret cautiously in ICU setting)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Urinalysis with microscopy (CPT 81003)",
          "rationale": "UTI as source of ongoing sepsis; myoglobinuria if rhabdomyolysis",
          "target": "Negative; dark urine may indicate myoglobinuria",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        }
      ],
      "Extended Workup (Second-line)": [
        {
          "item": "Aldolase (CPT 82085)",
          "rationale": "Muscle injury marker; may be elevated in CIM alongside CK; supports myopathic process",
          "target": "Elevated in CIM; normal in CIP",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "LDH (CPT 83615)",
          "rationale": "Non-specific marker of tissue damage; elevated in myopathy and hemolysis",
          "target": "Elevated in CIM",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Myoglobin (serum) (CPT 83874)",
          "rationale": "Muscle breakdown marker; elevated in CIM and rhabdomyolysis; renal toxicity risk",
          "target": "<90 ng/mL; elevated suggests muscle damage",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "URGENT"
        },
        {
          "item": "Urine myoglobin (CPT 83874)",
          "rationale": "Myoglobinuria from muscle breakdown; renal injury risk",
          "target": "Negative; positive indicates significant muscle damage",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "URGENT"
        },
        {
          "item": "Anti-ganglioside antibodies (GM1, GD1a, GQ1b) (CPT 86255)",
          "rationale": "Exclude GBS if clinical presentation unclear; GBS can develop during ICU stay",
          "target": "Negative; positive suggests GBS rather than ICUAW",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Acetylcholine receptor antibodies (CPT 86235)",
          "rationale": "Exclude myasthenia gravis if weakness pattern suggests NMJ disorder",
          "target": "Negative; positive suggests MG",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Anti-MuSK antibodies (CPT 86235)",
          "rationale": "Exclude MuSK-positive myasthenia if AChR negative but MG suspected",
          "target": "Negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Cortisol (random or AM) (CPT 82533)",
          "rationale": "Adrenal insufficiency from prolonged steroid use causing weakness; critical illness-related corticosteroid insufficiency",
          "target": "AM cortisol >10 mcg/dL generally adequate; <10 suggests insufficiency",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE"
        },
        {
          "item": "Free T4 (CPT 84439)",
          "rationale": "Hypothyroid myopathy in differential; thyroid dysfunction assessment",
          "target": "Normal",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Vitamin D (25-OH) (CPT 82306)",
          "rationale": "Deficiency is common in ICU patients and contributes to muscle weakness and impaired recovery",
          "target": ">30 ng/mL; supplement if <20 ng/mL",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Prealbumin (CPT 84134)",
          "rationale": "Nutritional status marker; low levels indicate protein malnutrition affecting muscle recovery",
          "target": ">15 mg/dL; low suggests inadequate nutrition",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "HbA1c (CPT 83036)",
          "rationale": "Chronic glycemic control assessment; poorly controlled diabetes increases ICUAW risk",
          "target": "<7% in general; assess baseline diabetes control",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        }
      ],
      "Rare/Specialized (Refractory or Atypical)": [
        {
          "item": "Paraneoplastic antibody panel (CPT 86255)",
          "rationale": "Paraneoplastic neuromyopathy in differential if cancer history or atypical features",
          "target": "Negative",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "EXT"
        },
        {
          "item": "Anti-VGCC antibodies",
          "rationale": "Lambert-Eaton myasthenic syndrome (LEMS) in differential; associated with small cell lung cancer",
          "target": "Negative; positive = LEMS",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Myositis-specific antibodies (Jo-1, Mi-2, SRP, MDA5)",
          "rationale": "Inflammatory myopathy in differential if CK markedly elevated and atypical course",
          "target": "Negative",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Heavy metals (lead, arsenic, thallium) (CPT 83018)",
          "rationale": "Toxic neuropathy mimic; occupational or environmental exposure",
          "target": "Normal",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Porphyrins (urine ALA, PBG) (CPT 84120)",
          "rationale": "Acute intermittent porphyria mimic (motor neuropathy, autonomic dysfunction)",
          "target": "Normal",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Muscle biopsy (CPT 20200)",
          "rationale": "Definitive differentiation CIM vs CIP when electrodiagnostics are inconclusive; shows thick filament (myosin) loss in CIM; rarely needed in practice",
          "target": "CIM: selective loss of thick (myosin) filaments, type 2 fiber atrophy, necrosis; CIP: denervation changes, grouped atrophy",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "EXT"
        },
        {
          "item": "Nerve biopsy (sural) (CPT 64795)",
          "rationale": "Rarely indicated; axonal degeneration in CIP; only when diagnosis is uncertain and alternative treatable diagnoses are considered",
          "target": "CIP: axonal degeneration of sensory and motor fibers; no inflammation",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        }
      ]
    },
    "Imaging & Studies": {
      "Essential/First-line": [
        {
          "item": "Nerve conduction studies (NCS) (CPT 95907-95913) / EMG (CPT 95886)",
          "timing": "When ICUAW suspected (typically after 1 week ICU stay with new weakness); ideally after sedation lightened to allow cooperation",
          "target": "CIP: reduced CMAP and SNAP amplitudes with normal conduction velocities (axonal pattern); CIM: reduced CMAP amplitudes with NORMAL SNAPs and myopathic MUP recruitment; Combined CINM: both axonal neuropathic and myopathic changes",
          "contraindications": "Anticoagulation (relative for needle EMG); unable to cooperate for volitional EMG",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "Direct muscle stimulation (DMS)",
          "timing": "When CIM vs CIP differentiation needed in uncooperative or sedated patients; specialized technique",
          "target": "CIM: reduced ratio of nerve-stimulated CMAP to direct muscle-stimulated CMAP (nerve:muscle ratio <0.5); CIP: preserved ratio with reduced CMAPs on both",
          "contraindications": "Requires specialized equipment; not widely available",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "-",
          "ICU": "URGENT"
        },
        {
          "item": "Chest X-ray (CPT 71046)",
          "timing": "On recognition of ICUAW; baseline for ventilator weaning assessment",
          "target": "Atelectasis, pleural effusion, diaphragm elevation (weakness), aspiration",
          "contraindications": "None significant",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "ECG (12-lead) (CPT 93000)",
          "timing": "Baseline; electrolyte abnormalities may cause arrhythmia; autonomic dysfunction assessment",
          "target": "Sinus rhythm; check for QTc prolongation, electrolyte-related changes",
          "contraindications": "None",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Ultrasound: diaphragm (CPT 76604)",
          "timing": "Assess diaphragm thickness and excursion; predicts ventilator weaning success; diaphragm atrophy develops within 48-72h of mechanical ventilation",
          "target": "Diaphragm thickness >2mm; thickening fraction >30% during inspiration; excursion >10mm; decreased values suggest diaphragm atrophy and prolonged weaning",
          "contraindications": "None significant",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "URGENT"
        },
        {
          "item": "Ultrasound: muscle (quadriceps, biceps) (CPT 76881)",
          "timing": "Quantify muscle wasting; serial measurements track progression; cross-sectional area decreases significantly within first week of ICU",
          "target": "Reduced muscle thickness and cross-sectional area compared to admission baseline; echogenicity changes suggest myopathic process",
          "contraindications": "None significant",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        }
      ],
      "Extended": [
        {
          "item": "MRI spine (whole) with and without contrast (CPT 72156)",
          "timing": "If spinal cord pathology suspected (upper motor neuron signs, sensory level)",
          "target": "Normal spinal cord; exclude compressive myelopathy, epidural abscess, infarction",
          "contraindications": "Pacemaker, metallic implants; patient stability for transport",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "MRI brain with and without contrast (CPT 70553)",
          "timing": "If central cause of weakness suspected (stroke, brainstem lesion)",
          "target": "Normal; exclude stroke, demyelination, structural lesion",
          "contraindications": "Same as MRI spine",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "Repeat NCS/EMG (CPT 95907-95913)",
          "timing": "At 2-4 weeks if initial study inconclusive or to assess prognosis and track recovery",
          "target": "Evolution of findings; persistent denervation predicts slower recovery; reinnervation signs suggest improvement",
          "contraindications": "Same as initial NCS/EMG",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Pulmonary function testing (formal spirometry) (CPT 94010)",
          "timing": "When patient can cooperate; assess respiratory muscle strength for weaning readiness; outpatient monitoring of recovery",
          "target": "FVC, MIP, MEP values; FVC >15 mL/kg supports weaning; serial improvement documents recovery",
          "contraindications": "Patient cooperation required",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "CT chest with contrast (CPT 71260)",
          "timing": "If pulmonary pathology suspected (PE, empyema) complicating weaning failure",
          "target": "Pulmonary embolism; pleural effusion; lung pathology",
          "contraindications": "Contrast allergy; renal impairment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "URGENT"
        }
      ],
      "Rare/Specialized": [
        {
          "item": "MRI muscle (thigh or upper arm) (CPT 73718)",
          "timing": "When inflammatory myopathy in differential; assesses muscle edema and fatty infiltration",
          "target": "CIM: diffuse muscle edema on STIR; inflammatory myopathy: focal/multifocal edema and enhancement",
          "contraindications": "MRI-incompatible implants",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Fluoroscopic sniff test (CPT 76000)",
          "timing": "Diaphragm paralysis evaluation when ultrasound is equivocal; paradoxical diaphragm motion",
          "target": "Normal bilateral diaphragm excursion; paradoxical motion indicates paralysis",
          "contraindications": "Radiation exposure; patient must be transported",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Phrenic nerve conduction study (CPT 95907)",
          "timing": "Assess phrenic nerve function directly; CIP may involve phrenic nerves causing diaphragm weakness",
          "target": "Reduced phrenic CMAP amplitude suggests CIP involving phrenic nerve; normal suggests preserved phrenic function",
          "contraindications": "Same as standard NCS",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "-",
          "ICU": "EXT"
        }
      ]
    },
    "Treatment": {
      "Acute/Emergent": [
        {
          "item": "Insulin (regular) infusion",
          "route": "IV",
          "indication": "Glycemic control to reduce ICUAW risk and severity; hyperglycemia is major modifiable risk factor",
          "dosing": {
            "doseOptions": [
              {
                "text": "Variable rate",
                "orderSentence": "Insulin (regular) infusion Variable rate IV"
              }
            ],
            "route": "IV",
            "instructions": "Insulin infusion per ICU protocol; target glucose 140-180 mg/dL (NICE-SUGAR target); avoid hypoglycemia <70 mg/dL; transition to subcutaneous when tolerating enteral nutrition",
            "orderSentence": "Insulin (regular) infusion Variable rate IV"
          },
          "contraindications": "Hypoglycemia risk; requires frequent glucose monitoring",
          "monitoring": "Glucose q1-2h during infusion; q4-6h when stable; watch for hypokalemia",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "DVT prophylaxis: Enoxaparin",
          "route": "SC",
          "indication": "Immobilized ICU patients at high risk for VTE; ICUAW patients are bedbound",
          "dosing": {
            "doseOptions": [
              {
                "text": "40 mg",
                "orderSentence": "DVT prophylaxis: Enoxaparin 40 mg SC"
              }
            ],
            "route": "SC",
            "instructions": "40 mg SC daily; adjust for renal function (CrCl <30: 30 mg SC daily or use UFH)",
            "orderSentence": "DVT prophylaxis: Enoxaparin 40 mg SC"
          },
          "contraindications": "Active bleeding; platelets <50K; CrCl <30 (use heparin instead)",
          "monitoring": "Platelets q3 days; anti-Xa if renal impairment; signs of bleeding",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE"
        },
        {
          "item": "DVT prophylaxis: Heparin SC (renal alternative)",
          "route": "SC",
          "indication": "VTE prophylaxis when enoxaparin contraindicated due to renal impairment",
          "dosing": {
            "doseOptions": [
              {
                "text": "5000 units",
                "orderSentence": "DVT prophylaxis: Heparin SC (renal alternative) 5000 units SC"
              }
            ],
            "route": "SC",
            "instructions": "5000 units SC q8h; use when CrCl <30 mL/min",
            "orderSentence": "DVT prophylaxis: Heparin SC (renal alternative) 5000 units SC"
          },
          "contraindications": "Active bleeding; HIT history",
          "monitoring": "Platelets q3 days for HIT surveillance",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE"
        },
        {
          "item": "Pneumatic compression devices",
          "route": "-",
          "indication": "VTE prophylaxis adjunct for all immobilized ICUAW patients; use in addition to pharmacologic prophylaxis",
          "dosing": {
            "doseOptions": [
              {
                "text": "Apply bilaterally on admission",
                "orderSentence": "Pneumatic compression devices Apply bilaterally on admission -"
              }
            ],
            "route": "-",
            "instructions": "Apply bilaterally; continue until patient is ambulatory; use as monotherapy only if pharmacologic anticoagulation contraindicated",
            "orderSentence": "Pneumatic compression devices Apply bilaterally on admission -"
          },
          "contraindications": "Acute DVT in affected limb; severe peripheral vascular disease",
          "monitoring": "Skin integrity daily; device function",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Stress ulcer prophylaxis: Famotidine",
          "route": "IV",
          "indication": "GI prophylaxis for mechanically ventilated patients with ICUAW",
          "dosing": {
            "doseOptions": [
              {
                "text": "20 mg",
                "orderSentence": "Stress ulcer prophylaxis: Famotidine 20 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "20 mg IV q12h; transition to PO when tolerating enteral feeds",
            "orderSentence": "Stress ulcer prophylaxis: Famotidine 20 mg IV"
          },
          "contraindications": "Severe renal impairment (dose adjust)",
          "monitoring": "None significant",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE"
        },
        {
          "item": "Stress ulcer prophylaxis: Pantoprazole",
          "route": "IV",
          "indication": "GI prophylaxis alternative; use if high bleed risk (coagulopathy, prior GI bleed)",
          "dosing": {
            "doseOptions": [
              {
                "text": "40 mg",
                "orderSentence": "Stress ulcer prophylaxis: Pantoprazole 40 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "40 mg IV daily; transition to PO when tolerating enteral feeds",
            "orderSentence": "Stress ulcer prophylaxis: Pantoprazole 40 mg IV"
          },
          "contraindications": "None significant",
          "monitoring": "C. difficile risk with prolonged use",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE"
        }
      ],
      "Symptomatic Treatments": [
        {
          "item": "Gabapentin",
          "route": "PO",
          "indication": "Neuropathic pain from CIP (burning, tingling, allodynia); common in recovery phase",
          "dosing": {
            "doseOptions": [
              {
                "text": "100 mg TID",
                "orderSentence": "Gabapentin 100 mg PO TID"
              },
              {
                "text": "300 mg TID",
                "orderSentence": "Gabapentin 300 mg PO TID"
              },
              {
                "text": "600 mg TID",
                "orderSentence": "Gabapentin 600 mg PO TID"
              },
              {
                "text": "900 mg TID",
                "orderSentence": "Gabapentin 900 mg PO TID"
              },
              {
                "text": "1200 mg TID",
                "orderSentence": "Gabapentin 1200 mg PO TID"
              }
            ],
            "route": "PO",
            "instructions": "Start 300 mg PO qHS; titrate by 300 mg/day q1-3 days; target 900-1800 mg/day divided TID; max 3600 mg/day; dose adjust for renal function",
            "orderSentence": "Gabapentin 100 mg PO TID"
          },
          "contraindications": "Severe renal impairment (dose adjust per CrCl); oversedation risk",
          "monitoring": "Sedation, dizziness, peripheral edema; renal function for dose adjustment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Pregabalin",
          "route": "PO",
          "indication": "Neuropathic pain alternative to gabapentin; may be better tolerated",
          "dosing": {
            "doseOptions": [
              {
                "text": "50 mg TID",
                "orderSentence": "Pregabalin 50 mg PO TID"
              },
              {
                "text": "75 mg BID",
                "orderSentence": "Pregabalin 75 mg PO BID"
              },
              {
                "text": "100 mg TID",
                "orderSentence": "Pregabalin 100 mg PO TID"
              },
              {
                "text": "150 mg BID",
                "orderSentence": "Pregabalin 150 mg PO BID"
              },
              {
                "text": "200 mg BID",
                "orderSentence": "Pregabalin 200 mg PO BID"
              },
              {
                "text": "300 mg BID",
                "orderSentence": "Pregabalin 300 mg PO BID"
              }
            ],
            "route": "PO",
            "instructions": "Start 75 mg PO BID; increase to 150 mg BID after 3-7 days; max 300 mg BID (600 mg/day); dose adjust for renal function",
            "orderSentence": "Pregabalin 50 mg PO TID"
          },
          "contraindications": "Renal impairment (dose adjust); angioedema history",
          "monitoring": "Sedation, weight gain, peripheral edema; renal function",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Duloxetine",
          "route": "PO",
          "indication": "Neuropathic pain and concurrent depression; dual benefit in ICUAW recovery",
          "dosing": {
            "doseOptions": [
              {
                "text": "30 mg daily",
                "orderSentence": "Duloxetine 30 mg PO daily"
              },
              {
                "text": "60 mg daily",
                "orderSentence": "Duloxetine 60 mg PO daily"
              },
              {
                "text": "90 mg daily",
                "orderSentence": "Duloxetine 90 mg PO daily"
              },
              {
                "text": "120 mg daily",
                "orderSentence": "Duloxetine 120 mg PO daily"
              }
            ],
            "route": "PO",
            "instructions": "Start 30 mg PO daily x 1 week, then increase to 60 mg daily; max 120 mg/day",
            "orderSentence": "Duloxetine 30 mg PO daily"
          },
          "contraindications": "Severe hepatic impairment; concurrent MAOIs; uncontrolled narrow-angle glaucoma",
          "monitoring": "LFTs; blood pressure; serotonin syndrome signs; mood",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Acetaminophen",
          "route": "PO/IV",
          "indication": "Musculoskeletal pain and general discomfort from immobility",
          "dosing": {
            "doseOptions": [
              {
                "text": "650 mg",
                "orderSentence": "Acetaminophen 650 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "650-1000 mg PO/IV q6h; max 4 g/day (2 g/day if hepatic impairment)",
            "orderSentence": "Acetaminophen 650 mg PO"
          },
          "contraindications": "Severe liver disease; hepatic impairment (reduce max dose)",
          "monitoring": "LFTs if prolonged use",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Melatonin",
          "route": "PO",
          "indication": "ICU delirium prevention and sleep-wake cycle restoration; disrupted sleep worsens ICUAW",
          "dosing": {
            "doseOptions": [
              {
                "text": "1 mg QHS",
                "orderSentence": "Melatonin 1 mg PO QHS"
              },
              {
                "text": "3 mg QHS",
                "orderSentence": "Melatonin 3 mg PO QHS"
              },
              {
                "text": "5 mg QHS",
                "orderSentence": "Melatonin 5 mg PO QHS"
              },
              {
                "text": "10 mg QHS",
                "orderSentence": "Melatonin 10 mg PO QHS"
              }
            ],
            "route": "PO",
            "instructions": "3-5 mg PO qHS; administer at consistent time to promote circadian rhythm",
            "orderSentence": "Melatonin 1 mg PO QHS"
          },
          "contraindications": "None significant",
          "monitoring": "Sleep quality; delirium assessment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE"
        },
        {
          "item": "Docusate sodium",
          "route": "PO",
          "indication": "Constipation from immobility and opioid use",
          "dosing": {
            "doseOptions": [
              {
                "text": "100 mg",
                "orderSentence": "Docusate sodium 100 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "100 mg PO BID",
            "orderSentence": "Docusate sodium 100 mg PO"
          },
          "contraindications": "GI obstruction",
          "monitoring": "Bowel function daily",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Senna",
          "route": "PO",
          "indication": "Constipation when docusate alone is insufficient",
          "dosing": {
            "doseOptions": [
              {
                "text": "8.6 mg",
                "orderSentence": "Senna 8.6 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "8.6-17.2 mg PO qHS; may increase to BID",
            "orderSentence": "Senna 8.6 mg PO"
          },
          "contraindications": "GI obstruction; acute abdomen",
          "monitoring": "Bowel function",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Polyethylene glycol (MiraLAX)",
          "route": "PO",
          "indication": "Constipation refractory to docusate and senna",
          "dosing": {
            "doseOptions": [
              {
                "text": "17 g",
                "orderSentence": "Polyethylene glycol (MiraLAX) 17 g PO"
              }
            ],
            "route": "PO",
            "instructions": "17 g PO daily dissolved in 8 oz water",
            "orderSentence": "Polyethylene glycol (MiraLAX) 17 g PO"
          },
          "contraindications": "GI obstruction",
          "monitoring": "Bowel function; electrolytes with prolonged use",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Sertraline",
          "route": "PO",
          "indication": "Depression and anxiety during prolonged ICU stay and recovery; common comorbidity in ICUAW",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg",
                "orderSentence": "Sertraline 25 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 25-50 mg PO daily; titrate by 25-50 mg q1-2 weeks; max 200 mg/day",
            "orderSentence": "Sertraline 25 mg PO"
          },
          "contraindications": "Concurrent MAOIs; QT prolongation risk",
          "monitoring": "Mood assessment; suicidality monitoring (first 4 weeks); serotonin syndrome signs",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Trazodone",
          "route": "PO",
          "indication": "Insomnia during ICU recovery when melatonin insufficient",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg QHS",
                "orderSentence": "Trazodone 25 mg PO QHS"
              },
              {
                "text": "50 mg QHS",
                "orderSentence": "Trazodone 50 mg PO QHS"
              },
              {
                "text": "100 mg QHS",
                "orderSentence": "Trazodone 100 mg PO QHS"
              },
              {
                "text": "150 mg QHS",
                "orderSentence": "Trazodone 150 mg PO QHS"
              }
            ],
            "route": "PO",
            "instructions": "Start 25-50 mg PO qHS; max 100 mg qHS for insomnia",
            "orderSentence": "Trazodone 25 mg PO QHS"
          },
          "contraindications": "Severe hepatic impairment; concurrent MAOIs",
          "monitoring": "Sedation; orthostatic hypotension; priapism (rare)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Cholecalciferol (Vitamin D3)",
          "route": "PO",
          "indication": "Vitamin D deficiency is prevalent in ICU patients and contributes to muscle weakness",
          "dosing": {
            "doseOptions": [
              {
                "text": "2000 IU",
                "orderSentence": "Cholecalciferol (Vitamin D3) 2000 IU PO"
              }
            ],
            "route": "PO",
            "instructions": "2000 IU PO daily for maintenance; 50,000 IU PO weekly x 8 weeks if deficient (<20 ng/mL), then 2000 IU daily",
            "orderSentence": "Cholecalciferol (Vitamin D3) 2000 IU PO"
          },
          "contraindications": "Hypercalcemia; granulomatous disease",
          "monitoring": "25-OH vitamin D level at 8-12 weeks; calcium",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        }
      ],
      "Second-line/Refractory": [
        {
          "item": "Amitriptyline",
          "route": "PO",
          "indication": "Neuropathic pain refractory to gabapentin/pregabalin; also helps insomnia",
          "dosing": {
            "doseOptions": [
              {
                "text": "10 mg QHS",
                "orderSentence": "Amitriptyline 10 mg PO QHS"
              },
              {
                "text": "25 mg QHS",
                "orderSentence": "Amitriptyline 25 mg PO QHS"
              },
              {
                "text": "50 mg QHS",
                "orderSentence": "Amitriptyline 50 mg PO QHS"
              },
              {
                "text": "75 mg QHS",
                "orderSentence": "Amitriptyline 75 mg PO QHS"
              },
              {
                "text": "100 mg QHS",
                "orderSentence": "Amitriptyline 100 mg PO QHS"
              }
            ],
            "route": "PO",
            "instructions": "Start 10-25 mg PO qHS; titrate by 10-25 mg q1-2 weeks; max 150 mg/day",
            "orderSentence": "Amitriptyline 10 mg PO QHS"
          },
          "contraindications": "Arrhythmia; recent MI; urinary retention; angle-closure glaucoma; elderly (anticholinergic burden)",
          "monitoring": "ECG at baseline and if dose >100 mg; anticholinergic side effects; QTc",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Lidocaine patch 5%",
          "route": "TOP",
          "indication": "Localized neuropathic pain; adjunctive to systemic agents",
          "dosing": {
            "doseOptions": [
              {
                "text": "1 patch",
                "orderSentence": "Lidocaine patch 5% 1 patch TOP"
              }
            ],
            "route": "TOP",
            "instructions": "Apply up to 3 patches to painful area for 12h on/12h off",
            "orderSentence": "Lidocaine patch 5% 1 patch TOP"
          },
          "contraindications": "Allergy to amide anesthetics; broken skin at application site",
          "monitoring": "Skin irritation at application site",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Methylphenidate",
          "route": "PO",
          "indication": "Severe fatigue and cognitive impairment during ICUAW recovery when non-pharmacologic measures insufficient",
          "dosing": {
            "doseOptions": [
              {
                "text": "5 mg",
                "orderSentence": "Methylphenidate 5 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 5 mg PO BID (morning and noon); max 20 mg BID; avoid afternoon dosing to prevent insomnia",
            "orderSentence": "Methylphenidate 5 mg PO"
          },
          "contraindications": "Severe anxiety; cardiac arrhythmia; uncontrolled hypertension; concurrent MAOIs",
          "monitoring": "Blood pressure; heart rate; appetite; sleep; mood; abuse potential",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Modafinil",
          "route": "PO",
          "indication": "Persistent fatigue during ICUAW recovery; alternative to methylphenidate",
          "dosing": {
            "doseOptions": [
              {
                "text": "100 mg",
                "orderSentence": "Modafinil 100 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 100 mg PO daily in AM; max 200 mg daily",
            "orderSentence": "Modafinil 100 mg PO"
          },
          "contraindications": "Severe hepatic impairment; cardiac arrhythmia",
          "monitoring": "Blood pressure; hepatic function; mood; sleep",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Disease-Modifying or Chronic Therapies": [
        {
          "item": "Early mobilization protocol",
          "route": "-",
          "indication": "Prevention and treatment of ICUAW; reduces duration of mechanical ventilation and ICU length of stay",
          "dosing": {
            "doseOptions": [
              {
                "text": "Structured protocol",
                "orderSentence": "Early mobilization protocol Structured protocol -"
              }
            ],
            "route": "-",
            "instructions": "Phase 1 (passive ROM) within 24-48h of ICU admission; Phase 2 (active-assisted exercises) when patient alert; Phase 3 (sitting, standing, ambulation) when hemodynamically stable; minimum 20-30 min sessions BID",
            "orderSentence": "Early mobilization protocol Structured protocol -"
          },
          "pretreatment": "Hemodynamic stability (MAP >65, no active vasopressor uptitration); adequate oxygenation (FiO2 <0.6, PEEP <10); no active arrhythmia; no active hemorrhage",
          "contraindications": "Active hemorrhage; unstable fractures; severe hemodynamic instability requiring high-dose vasopressors; acute MI; unsecured airway",
          "monitoring": "Heart rate, blood pressure, SpO2 during sessions; RASS sedation score; MRC sum score weekly",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Corticosteroid minimization",
          "route": "IV/PO",
          "indication": "Minimize corticosteroid exposure as major risk factor for CIM; taper to lowest effective dose as rapidly as clinically feasible",
          "dosing": {
            "doseOptions": [
              {
                "text": "Individualized taper",
                "orderSentence": "Corticosteroid minimization Individualized taper IV/PO"
              }
            ],
            "route": "IV/PO",
            "instructions": "Reassess corticosteroid indication daily; taper to lowest effective dose; discontinue if not clearly indicated; avoid concurrent use with NMBAs when possible",
            "orderSentence": "Corticosteroid minimization Individualized taper IV/PO"
          },
          "pretreatment": "Document clear indication for continued steroids; review alternatives",
          "contraindications": "Do not abruptly discontinue if patient has been on >7 days (adrenal suppression risk)",
          "monitoring": "Glucose (steroid-induced hyperglycemia); blood pressure; adrenal function if tapering after prolonged course",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Neuromuscular blocking agent (NMBA) minimization",
          "route": "IV",
          "indication": "Minimize NMBA exposure as risk factor for ICUAW; use train-of-four monitoring to avoid deep paralysis",
          "dosing": {
            "doseOptions": [
              {
                "text": "Individualized",
                "orderSentence": "Neuromuscular blocking agent (NMBA) minimization Individualized IV"
              }
            ],
            "route": "IV",
            "instructions": "If NMBA required (e.g., ARDS, refractory ICP), use lowest effective dose guided by train-of-four (TOF) monitoring; target 1-2/4 twitches; daily sedation/paralysis vacation if feasible; discontinue NMBA as soon as clinically possible",
            "orderSentence": "Neuromuscular blocking agent (NMBA) minimization Individualized IV"
          },
          "pretreatment": "Document clear indication (severe ARDS, refractory ICP, open abdomen)",
          "contraindications": "Concurrent high-dose corticosteroids (greatly increases CIM risk); avoid unless absolutely necessary",
          "monitoring": "Train-of-four q4h; daily attempt to discontinue; document indication daily",
          "ED": "-",
          "HOSP": "-",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Enteral nutrition (high-protein)",
          "route": "PO/EN",
          "indication": "Protein supplementation to support muscle preservation and recovery; protein catabolism is accelerated in ICUAW",
          "dosing": {
            "doseOptions": [
              {
                "text": "1.2-2.0 g/kg/day protein",
                "orderSentence": "Enteral nutrition (high-protein) 1.2-2.0 g/kg/day protein EN"
              }
            ],
            "route": "EN",
            "instructions": "Target protein 1.2-2.0 g/kg/day (adjusted body weight if obese); initiate enteral nutrition within 24-48h of ICU admission; caloric target 25-30 kcal/kg/day; avoid overfeeding",
            "orderSentence": "Enteral nutrition (high-protein) 1.2-2.0 g/kg/day protein EN"
          },
          "pretreatment": "Functional GI tract; hemodynamic stability (MAP >60 on stable or decreasing vasopressors)",
          "contraindications": "GI obstruction; uncontrolled shock (delay until resuscitated); bowel ischemia",
          "monitoring": "Prealbumin weekly; nitrogen balance; feeding tolerance (residuals); glucose",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Tight glycemic control protocol",
          "route": "IV/SC",
          "indication": "Target glucose 140-180 mg/dL to reduce ICUAW incidence; hyperglycemia independently increases CIM/CIP risk",
          "dosing": {
            "doseOptions": [
              {
                "text": "Insulin per protocol",
                "orderSentence": "Tight glycemic control protocol Insulin per protocol IV/SC"
              }
            ],
            "route": "IV/SC",
            "instructions": "IV insulin infusion in ICU targeting 140-180 mg/dL; transition to basal-bolus SC insulin when tolerating nutrition; avoid tight control <110 (increased mortality per NICE-SUGAR)",
            "orderSentence": "Tight glycemic control protocol Insulin per protocol IV/SC"
          },
          "pretreatment": "Active hypoglycemia",
          "contraindications": "Adrenal insufficiency (may require stress-dose steroids before aggressive glucose control)",
          "monitoring": "Glucose q1-2h on infusion; q4-6h on SC insulin; HbA1c at discharge",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Sedation minimization protocol",
          "route": "IV",
          "indication": "Daily sedation interruption and light sedation targets reduce ICUAW risk and facilitate early mobilization",
          "dosing": {
            "doseOptions": [
              {
                "text": "RASS target -1 to 0",
                "orderSentence": "Sedation minimization protocol RASS target -1 to 0 IV"
              }
            ],
            "route": "IV",
            "instructions": "Daily spontaneous awakening trial (SAT); target RASS -1 to 0; use analgesia-first approach (pain, delirium, then sedation); prefer dexmedetomidine or propofol over benzodiazepines (benzodiazepines increase delirium and ICUAW risk)",
            "orderSentence": "Sedation minimization protocol RASS target -1 to 0 IV"
          },
          "pretreatment": "Pain adequately controlled; no active seizures; no procedures requiring deep sedation",
          "contraindications": "Active seizures; procedures requiring deep sedation; severe agitation endangering patient safety (titrate to lowest necessary level)",
          "monitoring": "RASS q4h; CAM-ICU for delirium BID; pain assessment",
          "ED": "-",
          "HOSP": "-",
          "OPD": "-",
          "ICU": "STAT"
        }
      ]
    },
    "Other Recommendations": {
      "Referrals & Consults": [
        {
          "item": "Neurology consultation for diagnosis confirmation and electrodiagnostic planning (NCS/EMG) to differentiate CIM, CIP, and alternative diagnoses",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Physical therapy for early mobilization protocol initiation, passive/active ROM exercises, progressive strengthening, and functional mobility training",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Occupational therapy for upper extremity strengthening, ADL retraining, adaptive equipment assessment, and fine motor recovery",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "Speech-language pathology for swallowing evaluation given risk of pharyngeal weakness and aspiration in ICUAW patients",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "Respiratory therapy for ventilator weaning protocols, tracheostomy care, pulmonary rehabilitation, and secretion management",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Rehabilitation medicine (physiatry) for comprehensive rehabilitation planning and disposition (inpatient rehab vs skilled nursing facility)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Nutrition/Dietitian for enteral nutrition optimization, protein target (1.2-2.0 g/kg/day), caloric assessment, and micronutrient supplementation",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "Pulmonology for ventilator management optimization, weaning strategies, and tracheostomy decision if prolonged ventilation anticipated",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "URGENT"
        },
        {
          "item": "Pain management for refractory neuropathic pain not responding to first-line gabapentinoids",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Social work for discharge planning, family support, insurance authorization for rehabilitation, and community resources",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Psychology/Psychiatry for ICU-acquired PTSD, depression, anxiety, and cognitive dysfunction screening and treatment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Palliative care for goals-of-care discussion if severe ICUAW with poor prognosis, prolonged ventilator dependence, or significant comorbidities",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE"
        }
      ],
      "Patient Instructions": [
        {
          "item": "Recovery from ICU-acquired weakness typically takes weeks to months; CIM generally recovers faster than CIP (inform patient and family to set expectations)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Participate actively in all physical and occupational therapy sessions as tolerated to maximize recovery potential",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Report new or worsening weakness, numbness, tingling, or breathing difficulty to medical team immediately (may indicate complication or alternative diagnosis)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Continue home exercise program as prescribed by physical therapy between formal sessions to maintain gains",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Fall precautions: use assistive devices (walker, cane) as recommended; remove tripping hazards at home; do not attempt stairs without supervision until cleared",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Do not drive until strength and coordination have recovered sufficiently and cleared by neurologist or physiatrist",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Follow-up with neurology in 4-8 weeks after discharge for strength assessment and possible repeat NCS/EMG to track recovery",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Adequate nutrition with high-protein diet (1.2-2.0 g/kg/day protein) supports muscle recovery",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Mental health is important during recovery; report symptoms of depression, anxiety, or PTSD to healthcare provider (common after prolonged ICU stay)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        }
      ],
      "Lifestyle & Prevention": [
        {
          "item": "Early mobilization within 24-48 hours of ICU admission when hemodynamically stable to prevent and mitigate ICUAW",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "-"
        },
        {
          "item": "High-protein nutrition (1.2-2.0 g/kg/day) to support muscle preservation and recovery during critical illness",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Smoking cessation to optimize pulmonary function and tissue oxygenation for nerve and muscle recovery",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Glycemic control (target glucose 140-180 mg/dL in ICU; HbA1c <7% outpatient) to reduce ongoing neuromyopathy risk",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Avoid unnecessary corticosteroids and neuromuscular blocking agents to reduce ICUAW risk in current and future ICU admissions",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Graduated exercise program starting with low-intensity activities and progressing as tolerated to rebuild strength and endurance",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Frequent repositioning every 2 hours during immobility to prevent pressure ulcers and contractures",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "-"
        },
        {
          "item": "Adequate sleep hygiene with consistent sleep-wake cycles to promote neurological recovery and reduce delirium",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Vitamin D supplementation if deficient to support muscle function and bone health during recovery",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Alcohol avoidance as alcohol worsens neuropathy and impairs muscle recovery",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        }
      ]
    }
  },
  "differential": [
    {
      "diagnosis": "Guillain-Barr syndrome (GBS)",
      "features": "Ascending paralysis, areflexia, can develop during ICU stay; antecedent infection; albuminocytologic dissociation on LP; may be monophasic; usually not associated with prolonged steroid/NMBA exposure",
      "tests": "CSF analysis (elevated protein, normal WBC); NCS/EMG (demyelinating pattern in AIDP); anti-ganglioside antibodies; clinical timeline"
    },
    {
      "diagnosis": "Myasthenia gravis exacerbation",
      "features": "Fatigable weakness, ptosis, diplopia, bulbar symptoms; fluctuating course; intact reflexes (usually); responds to cholinesterase inhibitors",
      "tests": "AChR and MuSK antibodies; repetitive nerve stimulation (decremental); ice pack test; edrophonium test"
    },
    {
      "diagnosis": "Prolonged neuromuscular blockade effect",
      "features": "History of NMBA use; resolves within hours to days of NMBA discontinuation; train-of-four monitoring shows persistent block; no sensory involvement",
      "tests": "Train-of-four monitoring (incomplete recovery of twitches); clinical resolution after NMBA clearance (typically <48h); NCS/EMG normal after drug clearance"
    },
    {
      "diagnosis": "Spinal cord injury/compression",
      "features": "Sensory level; upper motor neuron signs below level (hyperreflexia, Babinski); bladder dysfunction; back pain",
      "tests": "MRI spine (cord compression, hemorrhage, infarction); clinical exam with sensory level"
    },
    {
      "diagnosis": "Central pontine myelinolysis (osmotic demyelination)",
      "features": "History of rapid sodium correction; quadriparesis with pseudobulbar features; locked-in syndrome; MRI brain lesion",
      "tests": "MRI brain (pontine or extrapontine demyelination on T2/FLAIR); serum sodium correction history"
    },
    {
      "diagnosis": "Rhabdomyolysis",
      "features": "Very elevated CK (typically >10,000 IU/L); dark urine; acute kidney injury; history of crush injury, statins, or seizures",
      "tests": "CK markedly elevated; urine myoglobin; renal function; clinical context"
    },
    {
      "diagnosis": "Acute necrotizing myopathy",
      "features": "Very elevated CK; myopathic EMG; may occur with statin use in ICU; requires muscle biopsy for definitive diagnosis",
      "tests": "CK markedly elevated; NCS/EMG (myopathic); muscle biopsy (necrosis without inflammation); anti-HMGCR or anti-SRP antibodies"
    },
    {
      "diagnosis": "Lambert-Eaton myasthenic syndrome (LEMS)",
      "features": "Proximal weakness improving with repeated effort; autonomic dysfunction; associated with small cell lung cancer; incremental response on RNS",
      "tests": "Anti-VGCC antibodies; repetitive nerve stimulation (incremental at high-rate); CT chest for malignancy"
    },
    {
      "diagnosis": "Disuse atrophy",
      "features": "Weakness proportional to immobility duration; normal NCS/EMG; no sensory changes; normal CK",
      "tests": "NCS/EMG normal; clinical context; muscle ultrasound (atrophy without echogenicity changes)"
    },
    {
      "diagnosis": "Hypothyroid myopathy",
      "features": "Proximal weakness; elevated CK; delayed relaxation of reflexes; other hypothyroid features (edema, cold intolerance)",
      "tests": "TSH elevated; free T4 low; CK elevated; NCS/EMG (myopathic)"
    },
    {
      "diagnosis": "Acute inflammatory myopathy (polymyositis/dermatomyositis)",
      "features": "Proximal weakness; elevated CK (often >5000); skin changes in dermatomyositis; may respond to immunosuppression",
      "tests": "CK markedly elevated; myositis-specific antibodies; MRI muscle (edema); muscle biopsy (inflammatory infiltrate)"
    },
    {
      "diagnosis": "Steroid myopathy (chronic)",
      "features": "Proximal weakness; normal CK; history of chronic corticosteroid use; no sensory involvement; gradual onset",
      "tests": "Normal CK; NCS/EMG (myopathic MUPs); clinical improvement with steroid taper; muscle biopsy (type 2 fiber atrophy without necrosis)"
    }
  ],
  "evidence": [
    {
      "recommendation": "ICUAW defined as MRC sum score <48/60 in cooperative ICU patients",
      "evidenceLevel": "Class I, Level B",
      "source": "[Stevens et al. Crit Care Med 2009](https://pubmed.ncbi.nlm.nih.gov/20838559/)"
    },
    {
      "recommendation": "Sepsis and multi-organ failure are primary risk factors for ICUAW",
      "evidenceLevel": "Class I, Level A",
      "source": "[De Jonghe et al. JAMA 2002](https://pubmed.ncbi.nlm.nih.gov/12472328/)"
    },
    {
      "recommendation": "NCS/EMG differentiates CIM (myopathic, normal SNAPs) from CIP (axonal sensorimotor)",
      "evidenceLevel": "Class I, Level B",
      "source": "[Latronico & Bolton. Lancet Neurol 2011](https://pubmed.ncbi.nlm.nih.gov/21939902/)"
    },
    {
      "recommendation": "Direct muscle stimulation (DMS) differentiates CIM from CIP in uncooperative patients",
      "evidenceLevel": "Class IIa, Level B",
      "source": "[Rich et al. Muscle Nerve 1996](https://pubmed.ncbi.nlm.nih.gov/10155996/)"
    },
    {
      "recommendation": "Hyperglycemia is independent risk factor; glycemic control reduces ICUAW incidence",
      "evidenceLevel": "Class I, Level A",
      "source": "[Van den Berghe et al. NEJM 2001](https://pubmed.ncbi.nlm.nih.gov/11942631/); [Hermans et al. Lancet 2007](https://pubmed.ncbi.nlm.nih.gov/18064865/)"
    },
    {
      "recommendation": "NICE-SUGAR target glucose 140-180 mg/dL (tight control increases mortality)",
      "evidenceLevel": "Class I, Level A",
      "source": "[NICE-SUGAR Investigators. NEJM 2009](https://pubmed.ncbi.nlm.nih.gov/19318384/)"
    },
    {
      "recommendation": "Corticosteroids combined with NMBAs greatly increase CIM risk",
      "evidenceLevel": "Class I, Level B",
      "source": "[De Jonghe et al. Crit Care Med 2009](https://pubmed.ncbi.nlm.nih.gov/20838559/); [Hermans et al. Intensive Care Med 2014](https://pubmed.ncbi.nlm.nih.gov/24441670/)"
    },
    {
      "recommendation": "Early mobilization reduces ICUAW incidence and improves outcomes",
      "evidenceLevel": "Class I, Level A",
      "source": "[Schweickert et al. Lancet 2009](https://pubmed.ncbi.nlm.nih.gov/19446324/)"
    },
    {
      "recommendation": "Early mobilization is safe in mechanically ventilated patients",
      "evidenceLevel": "Class I, Level B",
      "source": "[Morris et al. Crit Care Med 2008](https://pubmed.ncbi.nlm.nih.gov/18812812/)"
    },
    {
      "recommendation": "Minimizing sedation reduces delirium and ICUAW risk (ABCDEF bundle)",
      "evidenceLevel": "Class I, Level A",
      "source": "[Barnes-Daly et al. Crit Care Med 2017](https://pubmed.ncbi.nlm.nih.gov/28509742/)"
    },
    {
      "recommendation": "CIM has better prognosis than CIP; most CIM patients recover within 3-6 months",
      "evidenceLevel": "Class II, Level B",
      "source": "[Koch et al. Neurology 2012](https://pubmed.ncbi.nlm.nih.gov/22170878/); [Guarneri et al. J Neurol Neurosurg Psychiatry 2008](https://pubmed.ncbi.nlm.nih.gov/18339730/)"
    },
    {
      "recommendation": "Muscle ultrasound detects early muscle wasting in ICU patients",
      "evidenceLevel": "Class IIa, Level B",
      "source": "[Puthucheary et al. JAMA 2013](https://pubmed.ncbi.nlm.nih.gov/24108501/)"
    },
    {
      "recommendation": "Diaphragm ultrasound predicts weaning success",
      "evidenceLevel": "Class IIa, Level B",
      "source": "[DiNino et al. J Crit Care 2014](https://pubmed.ncbi.nlm.nih.gov/24365607/)"
    },
    {
      "recommendation": "Protein intake 1.2-2.0 g/kg/day recommended for critically ill patients",
      "evidenceLevel": "Class IIa, Level B",
      "source": "[McClave et al. JPEN 2016 (ASPEN/SCCM Guidelines)](https://pubmed.ncbi.nlm.nih.gov/26773077/)"
    },
    {
      "recommendation": "No specific pharmacologic treatment proven effective for CIM or CIP",
      "evidenceLevel": "Class I, Level C",
      "source": "[Hermans & Van den Berghe. NEJM 2015](https://pubmed.ncbi.nlm.nih.gov/26786743/)"
    },
    {
      "recommendation": "Electrical muscle stimulation may attenuate muscle wasting (emerging evidence)",
      "evidenceLevel": "Class IIb, Level C",
      "source": "[Routsi et al. Crit Care Med 2010](https://pubmed.ncbi.nlm.nih.gov/21078149/)"
    },
    {
      "recommendation": "ICU-acquired weakness is associated with increased mortality and prolonged mechanical ventilation",
      "evidenceLevel": "Class I, Level A",
      "source": "[Fan et al. CMAJ 2014](https://pubmed.ncbi.nlm.nih.gov/27011495/)"
    },
    {
      "recommendation": "ABCDEF bundle implementation reduces ICUAW and delirium",
      "evidenceLevel": "Class I, Level B",
      "source": "[Pun et al. Lancet Respir Med 2019](https://pubmed.ncbi.nlm.nih.gov/31889136/)"
    },
    {
      "recommendation": "Vitamin D deficiency is associated with ICU-acquired weakness",
      "evidenceLevel": "Class IIb, Level C",
      "source": "[Amrein et al. JAMA 2014](https://pubmed.ncbi.nlm.nih.gov/25268295/)"
    }
  ],
  "monitoring": [
    {
      "item": "MRC sum score (6 bilateral muscle groups: shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, ankle dorsiflexion)",
      "frequency": "Daily in ICU when patient cooperative; weekly on floor; each outpatient visit",
      "action": "MRC <48/60: confirm ICUAW diagnosis; intensify rehabilitation; if declining, reassess for alternative or superimposed diagnosis",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "Blood glucose",
      "frequency": "q1-2h on insulin drip; q4-6h on SC insulin; fasting + pre-meals on floor",
      "action": "Adjust insulin regimen; avoid hypoglycemia <70 mg/dL; persistent hyperglycemia worsens ICUAW",
      "ED": "STAT",
      "HOSP": "STAT",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "Respiratory function (FVC if cooperative; ventilator mechanics if intubated)",
      "frequency": "q4-6h if on ventilator; daily if on floor; each outpatient visit",
      "action": "Declining FVC: assess for pneumonia, fluid overload, worsening weakness; adjust ventilator support",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "Negative inspiratory force (NIF/MIP)",
      "frequency": "q4-6h if ventilator-dependent; daily on floor",
      "action": "NIF weaker than -20 cmH2O: not ready for extubation; continue respiratory therapy",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "Diaphragm ultrasound (thickness and excursion)",
      "frequency": "Weekly in ICU; monthly outpatient if diaphragm weakness present",
      "action": "Declining values: diaphragm atrophy worsening; adjust ventilator settings to promote diaphragm activity (avoid excessive support)",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "ROUTINE"
    },
    {
      "item": "CK (creatine kinase)",
      "frequency": "q48-72h in acute phase; weekly during recovery; PRN outpatient",
      "action": "Persistently or newly elevated: reassess for ongoing muscle injury; rhabdomyolysis; inflammatory myopathy",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "ROUTINE"
    },
    {
      "item": "Electrolytes (K, Mg, Phos, Ca)",
      "frequency": "Daily in ICU; q48-72h on floor; each outpatient visit",
      "action": "Replete aggressively; hypokalemia, hypomagnesemia, hypophosphatemia all worsen weakness",
      "ED": "STAT",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "Prealbumin/Albumin",
      "frequency": "Weekly in ICU and on floor; monthly outpatient",
      "action": "Low values: optimize nutrition; increase protein intake; nutrition consult",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "ROUTINE"
    },
    {
      "item": "Sedation level (RASS)",
      "frequency": "q4h in ICU",
      "action": "Over-sedation: reduce sedatives; switch from benzodiazepines to dexmedetomidine or propofol",
      "ED": "-",
      "HOSP": "-",
      "OPD": "-",
      "ICU": "STAT"
    },
    {
      "item": "Delirium screen (CAM-ICU)",
      "frequency": "q8-12h in ICU; daily on floor",
      "action": "Positive: delirium workup; reduce deliriogenic medications (benzodiazepines, anticholinergics); non-pharmacologic interventions",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "-",
      "ICU": "STAT"
    },
    {
      "item": "Skin integrity",
      "frequency": "Every shift in ICU; daily on floor",
      "action": "Pressure ulcer: reposition more frequently; wound care consult; pressure-relieving mattress",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "-",
      "ICU": "STAT"
    },
    {
      "item": "Functional status (Barthel Index or FIM score)",
      "frequency": "Weekly in hospital; each outpatient visit",
      "action": "Not improving: reassess rehabilitation plan; consider transfer to higher-level rehabilitation; assess for barriers to recovery",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "ROUTINE"
    },
    {
      "item": "NCS/EMG follow-up",
      "frequency": "At 2-4 weeks after initial; repeat at 3-6 months if recovering; annually if persistent deficits",
      "action": "No improvement at 3-6 months: consider muscle biopsy; reassess diagnosis; discuss prognosis with patient/family",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "ROUTINE"
    },
    {
      "item": "Depression/Anxiety screening (PHQ-9, GAD-7)",
      "frequency": "Weekly on floor; each outpatient visit",
      "action": "PHQ-9 >=10 or GAD-7 >=10: initiate treatment; psychiatry referral; assess for PTSD",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    }
  ],
  "disposition": [
    {
      "disposition": "Discharge home",
      "criteria": "MRC sum score >=48/60; ambulatory with or without assistive device; safe swallowing; adequate pain control on oral medications; stable respiratory function off supplemental O2; reliable outpatient follow-up; home exercise program established; family/caregiver support"
    },
    {
      "disposition": "Admit to floor",
      "criteria": "New-onset ICUAW identified in ICU patient transitioning to floor; MRC sum score 36-48/60; hemodynamically stable; off vasopressors; not ventilator-dependent; requires ongoing PT/OT; needs continued monitoring"
    },
    {
      "disposition": "Admit to ICU",
      "criteria": "Ventilator-dependent with ICUAW; acute respiratory failure from neuromuscular weakness; hemodynamic instability; need for continuous monitoring; initial evaluation of weakness in critically ill patient"
    },
    {
      "disposition": "Transfer to higher level of care",
      "criteria": "Need for specialized electrodiagnostic testing (DMS) not available locally; complex ventilator weaning requiring neuromuscular expertise; need for muscle biopsy for atypical presentation"
    },
    {
      "disposition": "Inpatient rehabilitation",
      "criteria": "Significant motor deficits (MRC sum score 36-48/60); able to tolerate 3 hours/day of therapy; medically stable; off mechanical ventilation (or stable tracheostomy with portable ventilator); good prognosis for functional improvement"
    },
    {
      "disposition": "Long-term acute care (LTAC)",
      "criteria": "Ventilator-dependent >21 days; unable to tolerate intensive rehabilitation; requires ongoing skilled nursing and ventilator weaning; medically complex"
    },
    {
      "disposition": "Skilled nursing facility (SNF)",
      "criteria": "Unable to tolerate 3 hours/day of therapy; requires ongoing nursing care; not ready for home but not requiring acute hospital level care"
    }
  ]
}
